Hikma Pharmaceuticals Plc (LON:HIK)‘s stock had its “neutral” rating restated by equities research analysts at JPMorgan Chase & Co. in a research note issued on Monday.

Several other research analysts also recently commented on HIK. Peel Hunt reaffirmed a “buy” rating and issued a GBX 2,340 ($30.44) price objective on shares of Hikma Pharmaceuticals Plc in a research note on Wednesday, March 15th. Stifel Nicolaus reaffirmed a “buy” rating and issued a GBX 2,550 ($33.17) price objective on shares of Hikma Pharmaceuticals Plc in a research note on Tuesday, April 4th. HSBC Holdings plc reaffirmed a “reduce” rating and issued a GBX 1,800 ($23.42) price objective on shares of Hikma Pharmaceuticals Plc in a research note on Friday, April 7th. Jefferies Group LLC downgraded Hikma Pharmaceuticals Plc to an “underperform” rating and decreased their price objective for the stock from GBX 2,162 ($28.13) to GBX 1,450 ($18.86) in a research note on Wednesday, May 17th. Finally, Numis Securities Ltd reaffirmed an “add” rating and issued a GBX 2,350 ($30.57) price objective on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, March 30th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of GBX 2,207.10 ($28.71).

Analyst Recommendations for Hikma Pharmaceuticals Plc (LON:HIK)

Shares of Hikma Pharmaceuticals Plc (LON:HIK) traded down 4.61% during midday trading on Monday, reaching GBX 1656.00. The company had a trading volume of 1,642,126 shares. The firm’s market capitalization is GBX 3.99 billion. The company has a 50 day moving average of GBX 1,879.59 and a 200 day moving average of GBX 1,888.89. Hikma Pharmaceuticals Plc has a 12-month low of GBX 1,573.00 and a 12-month high of GBX 2,703.00.

The company also recently declared a dividend, which will be paid on Thursday, May 25th. Shareholders of record on Thursday, April 6th will be issued a dividend of €0.22 ($0.25) per share. This represents a yield of 0.78%. The ex-dividend date is Thursday, April 6th. This is a boost from Hikma Pharmaceuticals Plc’s previous dividend of $0.21.

ILLEGAL ACTIVITY NOTICE: “JPMorgan Chase & Co. Reiterates “Neutral” Rating for Hikma Pharmaceuticals Plc (HIK)” was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/05/22/jpmorgan-chase-co-reiterates-neutral-rating-for-hikma-pharmaceuticals-plc-hik.html.

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

12 Month Chart for LON:HIK

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.